Literature DB >> 17447433

Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy.

G A Qureshi1, A A Qureshi, S A Memon, S H Parvez.   

Abstract

We have quantitated CSF and serum levels of Selenium, iron, copper and zinc by Atomic absorption spectrophotometer in 36 patients with parkinson's disease all on L-dopa therapy. Out of these 19 showed on or positive response to L-dopa where as 21 patients showed on and off response. These data were compared with 21 healthy controls. The results showed that serum levels of iron, copper and zinc remained unchanged where as in CSF, significant decrease in zinc was found in both on and on/off PD patients indicating the deficiency of zinc which continues in the worsening clinical condition of off patients. The level of copper remained unchanged in both on and on/off PD patients. Iron and selenium increase in CSF of both patients which is a clear evidence of relationship between increased iron and selenium level in brain which could be correlated with decrease in dopamine levels and oxidative stress in PD Patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17447433     DOI: 10.1007/978-3-211-33328-0_24

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  14 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review.

Authors:  Andreas M Grabrucker; Magali Rowan; Craig C Garner
Journal:  Drug Deliv Lett       Date:  2011-09

3.  Association of soil selenium, strontium, and magnesium concentrations with Parkinson's disease mortality rates in the USA.

Authors:  Hongbing Sun
Journal:  Environ Geochem Health       Date:  2017-02-07       Impact factor: 4.609

4.  Manganese and selenium concentrations in cerebrospinal fluid of seriously ill children.

Authors:  Tomáš Franěk; Karel Kotaška; Richard Průša
Journal:  J Clin Lab Anal       Date:  2017-02-15       Impact factor: 2.352

5.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

Review 6.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

Review 7.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

8.  Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson's disease.

Authors:  Hai-Wen Zhao; Jie Lin; Xue-Bao Wang; Xing Cheng; Jian-Yong Wang; Bei-Lei Hu; Yan Zhang; Xiong Zhang; Jian-Hong Zhu
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

9.  Assessing of plasma levels of iron, zinc and copper in Iranian Parkinson's disease.

Authors:  Rokhsareh Meamar; Hamidreza Nikyar; Leila Dehghani; Keivan Basiri; Mohammad Reza Aghaye Ghazvini
Journal:  Adv Biomed Res       Date:  2016-03-16

10.  Clinical Characteristics, Iron Metabolism and Neuroinflammation: New Insight into Excessive Daytime Sleepiness in Parkinson's Disease.

Authors:  Yang Hu; Peng Guo; Teng-Hong Lian; Li-Jun Zuo; Shu-Yang Yu; Li Liu; Zhao Jin; Qiu-Jin Yu; Rui-Dan Wang; Li-Xia Li; Ying-Shan Piao; Wei Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-21       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.